Here’s a 120-word summary of Huma Finance (HUMA) and Humacyte (HUMA):

@Huma Finance 🟣 $HUMA Finance is the first PayFi network, bridging real-world payment flows (like salaries, invoices, remittances) with decentralized finance. As a permissionless DeFi platform, it enables on‑chain credit without crypto collateral, tokenizing real‑world assets and powering global settlements via stablecoins across Solana, BNB, and Base. Since launch, it has processed over $4.5 billion in on‑chain volume with ~$103 million in active liquidity, delivering ~10.5% annual yields and up to 17.5× staking multipliers. Its native $HUMA token drives protocol governance, liquidity incentives, and rewards for ecosystem contributors. Supply is capped at 10 billion $HUMA, with emission schedules through 2029, including a 5% Season‑1 airdrop and future rounds. (bitget.com)

Humacyte (stock ticker HUMA) is a publicly traded biotech company developing off‑the‑shelf Human Acellular Vessels (HAVs)—bioengineered vascular grafts designed to reduce risks like infection and rejection. Their lead product, SYMVESS™, received FDA approval in December 2024 for treating vascular trauma. Humacyte has no debt, millions in cash, and potential Department of Defense contracts. The market sees HUMA as a high‑risk, high‑reward play in regenerative medicine, with a large addressable market (~$150 billion) and speculative upside if further approvals and commercial contracts materialize. (reddit.com, reddit.com)